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Introduction
Postherpetic neuralgia (PHN), the most common chronic complication of herpes zoster, is a debilitating neuropathic pain that persists long after resolution of visible cutaneous manifestations [1, 2] . PHN is a complex neuropathic pain condition that can manifest as a burning, stabbing, tingling sensation; tactile allodynia; or hyperalgesia [1, 3] . These symptoms generally worsen at night and frequently disturb sleep [4, 5] . Insomnia has long been known to be associated with chronic pain conditions [6, 7] , although the specific insomnia characteristics V C 2016 American Academy of Pain Medicine. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com vary by study and population. Because insomnia has been shown to worsen pain, mood, and daily physical functioning, it could negatively impact a PHN patient's clinical outcome [8, 9] . Although previous studies have consistently reported the high prevalence of insomnia in PHN patients [4, 5, 8] , there have not yet been any studies that sought to identify subgroups of PHN patients with a high risk for insomnia.
The Insomnia Severity Index (ISI) is a self-reporting instrument measuring patient perception of insomnia and its severity [10] . The ISI is brief, easy to administer and score, and provides relevant information for diagnosis and treatment. The ISI can be used to quantify insomnia severity and to provide a cut-off score to determine the clinical significance of subjective complaints. Also, the ISI has demonstrated good psychometric properties, including convergent validity, discriminant validity, and test-retest reliability [10, 11] .
The aim of this retrospective, cross-sectional study was to determine risk factors associated with clinical insomnia based on ISI score among demographics, painrelated variables, and rash severity and location in PHN patients.
Methods
This study was approved by the Institutional Review Board. The sample population from our outpatient clinic includes PHN patients who received treatment for their pain and who completed the ISI between June 2012 and June 2013. We defined PHN as dermatomal pain persisting or appearing for longer than 3 months after the onset of rash with a pain score 4 on a 0-10 numeric rating scale (NRS) [1] . We designed the study to exclude patients with severe or unstable medical or psychological conditions that would preclude completing the pain assessment. The excluded individuals were those who reported that the occurrence of insomnia predated the onset of herpes zoster by more than 1 month and those who were diagnosed with concomitant diseases that were unrelated to PHN and would likely have confounded the assessment of PHN. We also excluded patients with cancer, obstructive sleep apnea, or peripheral neuropathy. In addition, patients who did not receive appropriate antiviral therapy during the acute phase of herpes zoster were excluded.
The prevalence and severity of insomnia were assessed using the ISI data recorded at the first visit. The ISI includes seven items that assess sleep onset severity and sleep maintenance difficulties, patient satisfaction with current sleep pattern, insomnia interference with daily functioning, noticeable impairment of abilities attributed to sleep deprivation, and the degree of distress caused by sleep problems. Each item is graded on a five-point scale (0-4) so that the global score ranges from 0-28, with higher scores indicating more severe insomnia. According to the recommended score interpretation guidelines [10] , a global score of 0-7 indicates "no clinically significant insomnia," 8-14 indicates "subthreshold insomnia," 15-21 indicates "moderate clinical insomnia," and 22-28 indicates "severe clinical insomnia." For this study, we defined clinical insomnia as an ISI global score 15. Additional patient data were also collected, including age, gender, body mass index (BMI), medical history (diagnosed hypertension, diabetes mellitus), current PHN prescription medication, duration of PHN prescription medication use, duration of pain, pain score measured on a 0-10 NRS (patients were asked to rate the worst PHN pain that they had felt during the last 2 weeks), location of dermatomes involved in skin rash (trigeminal, cervical/upper extremity, thoracic, lumbosacral/lower extremity), severity of skin rash during the acute phase of herpes zoster (severe rash was defined as rash with 50 lesions and/or 2 dermatomes involved), presence of mechanical allodynia in the primary or adjacent skin areas (evoked sensations that are pathologically amplified responses to a light touch with a brush), and level of anxiety or depression assessed by the 14-item Hospital Anxiety and Depression Scale (HADS) [12] . The 14 HADS items, each scored on a 0-3 scale, were used to measure degree of anxiety (seven items) and depression (seven items). Thus, the two subscales range from 0-21, with higher scores indicating greater likelihood of an anxiety or depressive disorder. The cutoff value for identification of suspected cases is generally considered to be 8 [12] . The demographic data, pain-related clinical data, ISI data, and HADS data were obtained from all random patients by independent resident doctors during the preliminary medical examination.
Statistical Analysis
Continuous variables are shown as mean 6 SD, and categorical variables are shown as numbers (percentage). Logistic regression was used to estimate crude odds ratios (ORs) with 95% confidence intervals (CIs) to determine the degree of association between candidate effect variables and clinical insomnia (ISI score 15). The variables analyzed included demographic data (age, gender, BMI), duration of pain (< 1 year or 1 year), pain score (NRS < 7 or 7), presence of diagnosed hypertension or diabetes mellitus, location and severity of skin rash, presence of allodynia, and severity of anxiety and depression symptoms (HADS < 8 or 8).
Variables with a P value < 0.05 were considered statistically significant and were included in a multivariate logistic regression analysis to estimate adjusted ORs and 95% CIs. All statistical analyses were performed using the Statistical Package for the Social Sciences, version 20.0 (SPSS Inc., Chicago, IL, USA).
Results
Data from 162 patients who were treated for herpes zoster or PHN at our pain clinic were obtained from the electrical medical records. After excluding cases with acute herpes zoster, a total of 122 PHN patients were evaluated for eligibility. Five PHN patients who did not receive anti-viral treatment during the acute phase of herpes zoster were excluded. Four patients were excluded for having insomnia symptoms that emerged prior to herpes zoster infection. Two patients with incomplete data also were excluded. There were no patients with medical conditions relevant to the exclusion criteria. Finally, a total of 111 patients with PHN satisfied the study inclusion criteria and were included in the analyses. Patient demographics and clinical characteristics are shown in Table 1 . All enrolled patients were taking more than one type of PHN medication; 54% of patients were taking more than two types of PHN medications. In addition, 35% of patients had been taking PHN medications for longer than 1 year.
The mean global ISI score was 9.2, with wide variation, and 50.5% of patients reported mild to severe insomnia symptoms (ISI score 8) after pain development. Moderate to severe clinical insomnia (ISI score 15) was observed in 30.6% of PHN patients (Table 2) . In univariate analysis, high pain intensity (spontaneous pain with NRS 7), presence of mechanical allodynia, and high levels of anxiety and depression (HADS 8) were significantly associated with clinical insomnia (Table 3) . Prevalence of clinical insomnia increased gradually with patient age, but the difference was not statistically significant (v2 ¼ 4.207, P ¼ 0.240). Also, there were not statistically significant relationships between gender, body mass index and clinical insomnia (P ¼ 0.376, P ¼ 0.746, respectively). Patients with dermatomes in the trigeminal region (38.0%) or a cervical/upper extremity (47.0%) had a much higher prevalence of clinical insomnia than those with dermatomes in the thoracic region (25.4%) or a lumbosacral/lower extremity (21.4%), but the difference was not statistically significant (v2 ¼ 4.021, P ¼ 0.259). Patients with a severe skin rash during the acute phase of herpes zoster infection (36.6%) had a somewhat higher prevalence of clinical insomnia than those with mild to moderate rash severity (23.5%), but this difference was not statistically significant (v2 ¼ 2.239, P ¼ 0.135).
Multivariate logistic regression analyses revealed that high pain intensity (spontaneous pain with NRS 7) was the strongest predictor of clinical insomnia (OR ¼ 12.417, 95% CI: 2.990-51.561). However, presence of mechanical allodynia and high anxiety and depression level (HADS 8) were also significantly associated with clinical insomnia after adjusting for pain score (Table 3) .
Discussion
Our findings confirmed that insomnia is not uncommon in patients with PHN. We found that high pain intensity, presence of mechanical allodynia, and high level of anxiety/depression were strongly associated with clinical insomnia in our study population.
High pain intensity was revealed to be the strongest risk factor for insomnia in PHN patients. Similarly, most previous studies have reported that high pain intensity is significantly associated with insomnia symptoms in chronic pain patients [13] [14] [15] [16] . A recent evidence-based structured review supported the hypothesis that pain mediates sleep problems in chronic pain [17] . The results of our study also provide some evidence for the possibility that pain may mediate the sleep problems associated with PHN. In addition, insomnia has been reported to be significantly associated with pain sensitivity. Schuh-Hofer et al. demonstrated that a single night of total sleep deprivation can induce generalized hyperalgesia [18] . Thus, a disrupted sleep cycle can exacerbate pain, creating a vicious cycle in which insomnia caused by pain further aggravates that pain. From this aspect, insomnia is often seen as the secondary symptom of chronic pain. However, this point of view has shifted gradually as new evidence has emerged, pointing toward insomnia as the primary disorder from which chronic pain often develops [19, 20] . This indicates that an aggressive analgesic treatment does not always ensure the improvement of sleep problems in chronic pain patients. Therefore, our results suggest that insomnia might be considered a separate therapeutic target in PHN patients with severe pain and indicate the need for agents that have an impact on both pain and sleep in this population [21] .
PHN is a neuropathic pain syndrome whose most distinctive feature is allodynia, which is defined as pain evoked by innocuous stimuli [1, 2] . An interesting observation in this study was that PHN patients with mechanical allodynia on primary and adjacent skin lesions were Significant variables (P < 0.05) in univariate analysis were selected for multivariate analysis. Age and gender were included in the multivariate analysis because they were previously identified as risk factors for insomnia in the general population [25] . OR ¼ odds ratio; CI ¼ confidence interval; NRS ¼ numeric rating scale; HADS ¼ Hospital Anxiety and Depression Scale.
more likely to suffer from clinical insomnia than patients without allodynia. Peripheral nerve injury leads to an increase in the general excitability of nociceptive and multireceptive spinal cord neurons [2, 22] . Also, persistent noxious stimuli cause changes in the central nervous system that modify the mechanisms triggered by afferent stimuli [2, 22] . Therefore, central sensitization is expected to be the underlying pain mechanism of allodynia. Recent studies of animals with insomnia also showed that neuropathic pain-like stimuli suppress GABAergic transmission by way of increased GABA (c-aminobutyric acid) transporters that are located on activated astrocytes in the cingulate cortex [23, 24] . This indicates that the central mechanisms of neuropathic pain may affect insomnia rather than peripheral mechanisms acting on an affected peripheral nerve. Collectively, the current evidence suggests that the presence of allodynia reflects central neuroplasticity that is closely related to insomnia in PHN patients.
Centrally mediated symptoms such as anxiety, depression, and sleep disturbance are frequently observed in chronic pain conditions [13] . In a recent study using quantitative sensory tests, Schlereth et al. showed that anxiety and depression had a strong association with PHN pain magnitude [25] . Approximately 40% of adults with sleep problems have a diagnosable psychiatric disorder-usually depression and/or anxiety-that might be both a consequence of sleep deprivation and a risk factor for its development [26] . Moreover, Chiu et al. reported that depression and sleep disturbance are independently associated with a reduced pain threshold [27] . Thus, PHN patients with anxiety or depressive symptoms are highly susceptible to insomnia, and insomnia can be considered independent of these symptoms when devising treatment strategies for this subgroup, who are also more prone to poor clinical outcomes.
In the general population, age and gender are wellknown demographic risk factors for insomnia, which has a greater prevalence in women and older populations [28] . Interestingly, there is also evidence that female gender and older age are risk factors for PHN [29] . However, we did not find a significant relationship between demographic data, including age and gender, and clinical insomnia in PHN patients, even after analyzing each variable using various classification methods. At the outset, we predicted that greater rash severity and trigeminal dermatomes associated with skin lesions would influence the severity of insomnia because they had been reported as factors associated with increased risk for developing PHN, along with age and gender [29, 30] . However, the severity and location of skin lesions did not appear to have a causal relationship with clinical insomnia among the PHN patients in this study, despite the fact that we found a higher prevalence of insomnia among patients with skin lesions in the craniocervical region compared with those with lesions in other regions. Hence, pain characteristics suggestive of central sensitization and comorbid anxiety/depressive symptoms seem to be more important contributing factors for insomnia development in patients with PHN than demographic factors, rash severity, or rash location.
This study has several limitations. First, it was conducted in a single clinical setting and included a study population with a homogeneous racial background, leading to a small sample size, which might limit the ability to detect potentially significant associations. Secondly, our findings are cross-sectional in nature, limiting our ability to identify a causal relationship between insomnia and current pain or sleep treatments. Third, as shown in the result, there were PHN patients who were on various PHN medications. We could not control such potential confounders as anticonvulsant and antidepressant use, which could affect sleep [5] . Lastly, the ISI is based on the last 2 weeks of recalled data [10] and does not include parameters that are used to measure the degree of daytime activities, insomnia frequency, and duration or use of medication, which might be undetectable but could have an influence in determining the severity of insomnia. Therefore, these limitations of the ISI should be considered as well when interpreting the data. Better-controlled and larger studies are needed to evaluate the influence of insomnia and its correlates on clinical outcomes in PHN patients.
In conclusion, we found that severe pain intensity was the strongest risk factor for clinically significant insomnia in PHN patients. However, allodynia and comorbid anxiety/depressive symptoms were also independently associated with clinical insomnia. Therefore, insomnia should be addressed as an important part of pain management in PHN patients with these risk factors, especially in patients with severe pain.
